Benlysta (belimumab)
Links shared publicly online about this topic
Regulatory update - Benlysta (belimumab)
gsk.com — “Regulatory update - Benlysta (belimumab)” View full resource at gsk.com
Most Recently Shared on June 7, 2010 at 1:11 pm By:
eyeonfda Pharma and Health Lawyer
GSK files MAA 2 EMA 4 Benlysta (belimumab) 4 reducing disease activity in lupus patients receiving standardtherapy http://ow.ly/1V1Fb
BENLYSTA (Belimumab) drug information from MPR
empr.com — “BENLYSTA (Belimumab) drug information for Systemic lupus erythematosus from MPR including side effects, drug interactions, dosing, contraindications and warnings/precautions.” View full resource at empr.com
Most Recently Shared on June 10, 2011 at 4:51 am By:
MPR News: BENLYSTA: Monograph added. http://bit.ly/ltyOH0
Benlysta (belimumab): A New Lupus Medication on the Horizon - Conditions and Treatments (Professional) - HSS
hss.edu — “Benlysta (belimumab): A New Lupus Medication on the Horizon - Conditions and Treatments (Professional) - HSS” View full resource at hss.edu
Most Recently Shared on November 16, 2009 at 8:23 pm By:
@lupussurvivors @Cure4Lupus: Benlysta (belimumab): A New Lupus Medication on the Horizon: http://tinyurl.com/yfk3sds
RxEconsult, LLC - Benlysta (belimumab) for systemic lupus erythematosus (SLE)
rxeconsult.com — “RxEconsult, LLC - Benlysta (belimumab) for systemic lupus erythematosus (SLE)” View full resource at rxeconsult.com
Most Recently Shared on October 7, 2011 at 11:44 pm By:
RxEconsult. If you are in need of healthcare services or information, please visit RxEconsult.
Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.
Dr. Ogbru has written several journal articles. In 1997, he shared an award from the American Journal of Pain Management for Outstanding Contribution to the Interdisciplinary Pain Management Literature. Over the last 12 years Dr. Ogbru has held several roles in the pharmaceutical industry, including Director of Global Medical Information and Communication." /> Ome Ogbru, PharmD Active Health Library, Doctor, Pharmacist, and PharmD
#Benlysta (#belimumab) for systemic #lupus erythematosus (SLE) http://t.co/3TpzMnEj #Medications #healthcare
Benlysta (belimumab) Side Effects, Warnings and Precautions, Dosing, and mechinisam of action is included on MedicineNet.com
medicinenet.com — “Information on the drug Benlysta (belimumab) prescribed for the treatment off systemic lupus erythematosus. Side effects, warnings and precautions, and drug interactions are included.” View full resource at medicinenet.com
Most Recently Shared on March 10, 2011 at 6:00 pm By:
Benlysta (belimumab) Approved for Lupus Treatment http://bit.ly/eEdlQQ
GlaxoSmithKline and Human Genome Sciences receive European authorisation for Benlysta® (belimumab)
us.gsk.com — “GlaxoSmithKline and Human Genome Sciences receive European authorisation for Benlysta® (belimumab)” View full resource at us.gsk.com
Most Recently Shared on July 14, 2011 at 1:51 pm By:
eyeonfda Pharma and Health Lawyer
GSK and HGS get EU authorization for Benlysta® (belimumab) http://ow.ly/5Eq5m #lupus
Stacy Ardoin, MD, Carlos Lozada, MD: Benlysta (belimumab) for lupus | CurrentMedicine.tv
currentmedicine.tv — “September 1, 2010 Lupus has been a challenging disease with little clinical progress for decades. This may change soon if a new drug branded as Benlysta” View full resource at currentmedicine.tv
Most Recently Shared on September 1, 2010 at 2:59 pm By:
Healthcare Channel Health Site
New Video: Benlysta (belimumab) to treat lupus: the BLISS trials evaluated by two experts http://tinyurl.com/3xy758u $HGSI #lupus
Human Genome Sciences Announces Presentation of Additional Phase 3 SLE Study Results for BENLYSTA (Belimumab) | Lupus Research Institute
lupusresearchinstitute.org — “The Lupus Research Institute (LRI) provides LupusResearchInstitute.org to help scientists and physicians, patients, and their families champion novel and innovative lupus research. On the homepage you will find information about lupus and the LRI as well as lupus research and news.” View full resource at lupusresearchinstitute.org
Most Recently Shared on June 25, 2010 at 7:40 pm By:
News from #Lupus2010: HGS Announces Presentation of Additional Phase 3 SLE Study Results for BENLYSTA® http://ht.ly/23op4
PharmaLive: GlaxoSmithKline and Human Genome Sciences Receive European Authorization for Benlysta (Belimumab)
pharmalive.com — “PharmaLive: GlaxoSmithKline and Human Genome Sciences Receive European Authorization for Benlysta (Belimumab)” View full resource at pharmalive.com
Most Recently Shared on July 14, 2011 at 6:27 pm By:
PharmaLive Pharma and Health News
Daily Advantage - Benlysta OK'd in Europe - http://tinyurl.com/644cxjs
News: Human Genome seeks FDA nod to market lupus drug Benlysta (belimumab) http://bit.ly/ct6bf2 - #health
reuters.com — “News: Human Genome seeks FDA nod to market lupus drug Benlysta (belimumab) http://bit.ly/ct6bf2 - #health” View full resource at reuters.com
Most Recently Shared on June 10, 2010 at 8:45 pm By:
Hisham Rana, MD Doctor and Physician
News: Human Genome seeks FDA nod to market lupus drug Benlysta (belimumab) http://bit.ly/ct6bf2 - #health
GlaxoSmithKline And Human Genome Sciences Announce FDA Priority Review Designation For Benlysta (belimumab) - QualityPoint Technologies
qualitypointtech.net — “GlaxoSmithKline PLC (GSK) and Human Genome Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted a priority review designation to Benlysta (belimumab) as a potential treatment for systemic lupus erythematosus (SLE). A priority review designation is granted to drugs that, if approved, offer major advances in treatment or provide a treatment where no adequate therapy exists. The FDA has assigned belimumab a Prescription Drug User Fee Act (PDUFA) target date of 9 Dec” View full resource at qualitypointtech.net
Most Recently Shared on August 21, 2010 at 12:51 pm By:
GlaxoSmithKline And Human Genome Sciences Announce FDA Priority Review Designation For Benlysta® (belimumab): Gla... http://bit.ly/bKAZnD
PharmaLive: Human Genome Sciences and GlaxoSmithKline Announce FDA Approval of Benlysta (Belimumab) for Treatment of Systemic Lupus Erythematosus
pharmalive.com — “PharmaLive: Human Genome Sciences and GlaxoSmithKline Announce FDA Approval of Benlysta (Belimumab) for Treatment of Systemic Lupus Erythematosus” View full resource at pharmalive.com
Most Recently Shared on March 10, 2011 at 7:36 pm By:
PharmaLive Pharma and Health News
Daily Advantage - FDA Approves Lupus Drug - http://tinyurl.com/48s7f3b
News: Glaxo, Human Genome get fast review for first new systemic lupus drug in 50 years http://bit.ly/cfVjum - Benlysta (belimumab) #health
reuters.com — “News: Glaxo, Human Genome get fast review for first new systemic lupus drug in 50 years http://bit.ly/cfVjum - Benlysta (belimumab) #health” View full resource at reuters.com
Most Recently Shared on August 19, 2010 at 2:45 pm By:
Hisham Rana, MD Doctor and Physician
News: Glaxo, Human Genome get fast review for first new systemic lupus drug in 50 years http://bit.ly/cfVjum - Benlysta (belimumab) #health
HUMAN GENOME SCIENCES TO HOST NOVEMBER 2ND CONFERENCE CALL TO DISCUSS TOP-LINE RESULTS FROM SECOND PHASE 3 TRIAL OF BENLYSTA" (BELIMUMAB) IN SYSTEMIC LUPUS ERYTHEMATOSUS - HGS
hgsi.com — “Human Genome Sciences is an emerging pharmaceutical company with the mission to predict, prevent, detect, treat and cure disease.” View full resource at hgsi.com
Most Recently Shared on October 29, 2009 at 3:39 pm By:
Stay tuned Monday for results from HGS's second Phase 3 clincal trial for Benlysta, a new treatment in development... http://bit.ly/4oivM9
GlaxoSmithKline And Human Genome Sciences Receive Positive Opinion In Europe From The CHMP For Benlysta® (belimumab) http://sns.mx/16bUy8
snsanalytics.com — “GlaxoSmithKline And Human Genome Sciences Receive Positive Opinion In Europe From The CHMP For Benlysta® (belimumab) http://sns.mx/16bUy8” View full resource at snsanalytics.com
Most Recently Shared on May 21, 2011 at 8:55 am By:
GlaxoSmithKline And Human Genome Sciences Receive Positive Opinion In Europe From The CHMP For Benlysta® (belimumab) http://sns.mx/16bUy8
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Related WisdomCards
Related Health Centers
Featuring the top 3 experts for this topic
-
eyeonfda
Author of the blog Eye on FDA - www.eyeonfda.com
-
MPR
eMPR.com provides up-to-date, concise drug information at the point-of-care.
-
Hosp Special Surgery
Hospital for Special Surgery (HSS) is a world leader in orthopedics, rheumatology and rehabilitation. HSS is ranked #1 in the nation for orthopedics.
Advertisement
